High-Dose Atorvastatin Raises Threshold of Contrast-Induced Nephropathy in Diabetic Patients Undergoing Elective Coronary Intervention: A Randomized Controlled Study

Table 2

Demographic, clinical, echocardiographic, and laboratory data of the two groups.

Parameter	Placebo group	Statin group	value
Age in years (mean ± SD)	59.3 ± 7.1	58.3 ± 8.5	0.4
Sex, males (%)	47 (47)	47 (47)	1.0
Smokers (%)	19 (19)	20 (20)	0.6
HTN (%)	38 (38)	39 (39)	0.9
Previous PCI (%)	4 (4)	4 (4)	1.0
Duration of DM in years (mean ± SD)	7.0 ± 3.5	7.1 ± 4.2	0.8
Insulin therapy (%)	53 (53)	42 (42)	0.1
Heart failure (%)	24 (24)	20 (20)	0.5
Body mass index (mean ± SD)	27.2 ± 3.1	27.2 ± 3.4	1.0
Heart rate in beats/min. (mean ± SD)	84.6 ± 14.8	84.4 ± 14.3	0.9
Systolic blood pressure in mmHg (mean ± SD)	131.9 ± 18.0	134.0 ± 19.5	0.4
Diastolic blood pressure in mmHg (mean ± SD)	83.4 ± 10.6	84.4 ± 10.3	0.5
Segmental wall motion abnormalities (%)	33 (33)	35 (35)	0.8
EF (%) (mean ± SD)	59.7 ± 9.8	59.0 ± 9.8	0.6
Volume of contrast in ml (mean ± SD)	123.0 ± 49.1	119.8 ± 47.6	0.6
Time of X-ray exposure in min. (mean ± SD)	12.1 ± 5.6	11.9 ± 5.4	0.8
Coronary procedure
PCI with one stent (%)	63 (63)	70 (70)	0.3
PCI with two stents (%)	31 (31)	22 (22)
PCI with > two stents (%)	6 (6)	8 (8)
TIMI flow
TIMI I (%)	2 (2)	0 (0)	0.3
TIMI II (%)	5 (5)	4 (4)
TIMI III (%)	93 (93)	96 (96)
Baseline serum creatinine in umol/L (mean ± SD)	1.191 ± 0.17	1.190 ± 0.16	0.9
Follow-up serum creatinine in umol/L (mean ± SD)	1.4 ± 0.3	1.3 ± 0.2	0.02
Hemoglobin in mg/dL (mean ± SD)	12.7 ± 1.8	11.8 ± 1.3	0.1
CIN (%)	18 (18)	6 (6)	0.0001

Statistically significant.